The Lead Discovery Center GmbH (LDC) announces today that an innovative kinase inhibitor program licensed to Bayer Pharma AG, Germany (Bayer) last year, has reached an important transition milestone.
Bayer has successfully advanced this kinase inhibitor program into pre-clinical development with the goal of eventually advancing this candidate into oncology clinical development. Protein kinases are key components of cellular signaling pathways that control tumor cell growth, metabolism and metastasis. They have therefore become prime targets for oncology drug discovery and clinical development. Read more


Landsvirkjun, the Icelandic energy provider, has been examining how realistic it would be to build the world’s longest submarine electric cable, which will enable sales of
Die
Stuttgart, July 26, 2010-The two large Stuttgart automotive suppliers MAHLE and BEHR have agreed that MAHLE will take over shares in BEHR in several stages.